Compare UVV & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UVV | CSTL |
|---|---|---|
| Founded | 1886 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | 2019 |
| Metric | UVV | CSTL |
|---|---|---|
| Price | $54.14 | $40.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $46.00 |
| AVG Volume (30 Days) | 176.2K | ★ 331.6K |
| Earning Date | 02-09-2026 | 02-26-2026 |
| Dividend Yield | ★ 6.04% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.44 | N/A |
| Revenue | ★ $2,987,411,000.00 | $343,530,000.00 |
| Revenue This Year | $3.21 | $2.54 |
| Revenue Next Year | $1.02 | N/A |
| P/E Ratio | $12.24 | ★ N/A |
| Revenue Growth | 3.01 | ★ 10.15 |
| 52 Week Low | $49.96 | $14.59 |
| 52 Week High | $67.33 | $42.18 |
| Indicator | UVV | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 55.01 | 57.91 |
| Support Level | $53.53 | $38.73 |
| Resistance Level | $56.02 | $41.60 |
| Average True Range (ATR) | 0.89 | 1.58 |
| MACD | 0.16 | -0.12 |
| Stochastic Oscillator | 59.57 | 62.75 |
Universal Corp is an international leaf tobacco supplier. The company procures leaf tobacco from farmers, processes it, and sells it to companies that manufacture consumer tobacco products. Universal does not manufacture or sell any consumer products itself. The company's segments include Tobacco Operations and Ingredients Operations. It generates maximum revenue from the Tobacco Operations segment. Geographically, it derives a majority of revenue from the United States. The company operates in the USA, Belgium, China, Egypt, Philippines, Germany, and Other Countries with majority of revenue from USA.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.